Herduo 250 mg Tablet
Request Pricing & Availability
Fill in your details below and our clinical team will get back to you with pricing & availability within 24 hours.
Similar Products
| Product | Manufacturer / Marketed By | Price |
|---|---|---|
Hertab 250 mg Tablet
|
Hetero Healthcare | Ask for Price |
Tykerb 250 mg Tablet
|
Novartis | Ask for Price |
Combinib 250 mg Tablet
|
Cipla | Ask for Price |
Description
Herduo 250 mg Tablet, containing lapatinib as the active ingredient, is prescribed for treating advanced breast cancer. It can be used alone or in conjunction with other medications to target hormone-sensitive cells and rapidly dividing cancer cells that overexpress the human epidermal growth factor receptor-2 protein. While undergoing treatment with Herduo 250 mg Tablet, common side effects such as nausea, vomiting, fatigue, weakness, itchiness, dry skin, reduced appetite, indigestion, constipation, mouth sores, stomach discomfort, sleep disturbances, joint or back pain, coughing, breathing difficulties, headaches, and more may occur. If you encounter severe allergic reactions, skin rashes, or issues with your heart, liver, or lungs, contact your healthcare provider promptly. Notify your physician immediately at the first sign of diarrhea or dehydration, and ensure regular monitoring of
Related Products
-
Lenvitib 10 mg Capsule
LenvatinibPrice on request
Request pricing -
Lucimird 1 mg Capsule
Price on request
Request pricing -
Luciorfor 17.2 mg Tablet
Price on request
Request pricing -
Luciorfor 14.5 mg Tablet
Price on request
Request pricing -
Luciorfor 9 mg Tablet
Price on request
Request pricing -
Luciorfor 5.5 mg Tablet
Price on request
Request pricing -
Luciorfor 2.5 mg Tablet
Price on request
Request pricing -
Luciorfor 0.8 mg Tablet
Price on request
Request pricing -
LuciPemafib 0.1 mg Tablet
Price on request
Request pricing -
LuciVeric 10 mg Tablet
Price on request
Request pricing -
LuciLemb 5 mg Tablet
Price on request
Request pricing -
LuciElag 200 mg Tablet
Price on request
Request pricing
Related Reading
-
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
-
First-Line Palbociclib Combination Boosts PFS in HR+/HER2+ mBC – PATINA Findings
Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 1, 2026. n Metastatic breast cancer (mBC) remains
-
Atirmociclib and Fulvestrant Together Delay Cancer Progression in HR+/HER2– Cases
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 23, 2026. Advancements in breast cancer treatment continue
-
Healing After Radiation: Is a Nipple-Sparing Mastectomy Possible?
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 20, 2026. n For many years, patients who
-
Oral SERDs Explained: The New Hormone Therapy Option After Endocrine Resistance in HR+ Breast Cancer
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 25, 2026. n Hormone receptor-positive, HER2-negative breast cancer
-
Does Ribociclib Still Help After 3 Years? The NATALEE Trial’s 4-Year Follow-Up Answers
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 21, 2026. n For patients with hormone receptor–positive,
Shipping & Delivery
- Ships from
- India, worldwide delivery
- Order processing
- 1–3 business days after checks
- Transit time
- 5–7 business days by express courier
- Tracking
- Tracking number sent by email or SMS
- Packaging
- Discreet, tamper-evident, cold-chain available
- Duties & taxes
- Payable by the recipient on import
Only logged in customers who have purchased this product may leave a review.


Reviews
Clear filtersThere are no reviews yet.